{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:05:24Z","timestamp":1779703524750,"version":"3.53.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"am","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaplastic thyroid cancer (ATC) is an extremely rare cancer with very poor prognosis. Targeted therapies have improved outcomes in selected patients, but molecular testing is often difficult because of the aggressive course, rapid clinical deterioration, and long turnaround times. This study aimed to provide real-world evidence on the management and outcomes of ATC and to evaluate the prognostic impact of molecular testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This multicentric, retrospective study included patients diagnosed with ATC between 1992-2024 from the REGETNE-Thyroid Network. Factors associated with overall survival (OS) were analyzed using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>214 patients were included (median age 70.8\u2009years; 56.5% female). Median OS was 4.5\u2009months. Access to molecular testing (HR 0.42, p\u2009=\u20090.001) and BRAF V600E mutation (HR 0.50, p\u2009=\u20090.008) were associated with longer OS, whereas TERT promoter mutations were associated with shorter survival (HR 2.80, p\u2009=\u20090.014). Local surgery showed a favorable prognostic association, regardless of stage (IVa\/IVb: HR 0.54, p\u2009=\u20090.026; IVc: HR 0.36, p\u2009&amp;lt;\u20090.001). In metastatic disease, immunotherapy (HR 0.31; p\u2009&amp;lt;\u20090.001), tyrosine kinase inhibitors (HR 0.40; p\u2009=\u20090.002) and their combination (HR 0.24; p\u2009=\u20090.001) significantly improved OS, whereas chemotherapy did not (HR 0.76; p\u2009=\u20090.096). Targeted therapy, used predominantly (&amp;gt;95%) in BRAF V600E-mutated ATC, was also associated with longer survival (HR 0.40; p\u2009=\u20090.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Molecular testing was associated with improved survival in ATC, likely driven by the identification of actionable alterations with effective targeted therapies. Local management is key in all stages. Our findings also support immunotherapy, tyrosine kinase inhibitors and their combinations as key therapeutic options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag158","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:46:15Z","timestamp":1779277575000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort"],"prefix":"10.1093","author":[{"given":"Pau","family":"Mascar\u00f3-Baselga","sequence":"first","affiliation":[{"name":"Vall Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Miguel","family":"Rodellar Sanz","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Nunes","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil , Lisbon,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[{"name":"Vall Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Vall Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gonz\u00e1lez Merino","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina Cerrillo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antia","family":"Fernandez-Pombo","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Santiago , Santiago de Compostela,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Iglesias-Alvarez","sequence":"additional","affiliation":[{"name":"Central University Hospital of Asturias , Oviedo,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Ceballos Lenza","sequence":"additional","affiliation":[{"name":"University Hospital of Canarias , San Cristobal de La Laguna,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Plana Serrahima","sequence":"additional","affiliation":[{"name":"Catalan Intitute of Oncology L'Hospitalet, L'Hospitalet de Llobregat ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Bella Cueto","sequence":"additional","affiliation":[{"name":"Parc Taul\u00ed Hospital Universitari. Institut d\u2018Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT-CERCA). Universitat Aut\u00f2noma de Barcelona , Sabadell,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Isidro","sequence":"additional","affiliation":[{"name":"University Hospital of A Coru\u00f1a, A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez Trufero","sequence":"additional","affiliation":[{"name":"Miguel Servet University Hospital , Zaragoza,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria (IdISSC), EURACAN Referral Centre Hospital Cl\u00ednico San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Martinez","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Santiago , Santiago de Compostela,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Crespo","sequence":"additional","affiliation":[{"name":"Burgos University Hospital , Burgos,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Jimeno","sequence":"additional","affiliation":[{"name":"Marqu\u00e9s de Valdecilla University Hospital , Santander,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"University Hospital Complex of Vigo , Vigo,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ayala de Miguel","sequence":"additional","affiliation":[{"name":"Hospital Complex of C\u00e1ceres , C\u00e1ceres,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alcazar","sequence":"additional","affiliation":[{"name":"Severo Ochoa University Hospital , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mart\u00ednez-Badal","sequence":"additional","affiliation":[{"name":"Vall Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Vall Hebron Institute of Oncology , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso Gordoa","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag158\/68380203\/oyag158.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag158\/68380203\/oyag158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:35:43Z","timestamp":1779701743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article\/doi\/10.1093\/oncolo\/oyag158\/8692456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag158","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"oyag158"}}